Krystal Biotech's Vyjuvek was nominated for a 2026 Prix Galien award, recognizing its work in genetic medicine. The story reports no award win or change to company results, so its outlook is unchanged.
The nomination recognizes Vyjuvek's work in genetic medicine. But the story reports no award win, change in treatment use, or change in company results. It therefore does not change how we read the company's business outlook.
Follow Krystal Biotech (KRYS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KRYS